Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RSVpreF vaccine in adults aged 60 years and older
CTR20251196Phase 3Suspended
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV), sponsored by Pfizer. Started Apr 2025; status: suspended.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20251196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251196.